Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

被引：77

作者：

Wang, Michael ^{[1
]}

Rule, Simon ^{[2
]}

Zinzani, Pier Luigi ^{[3
]}

Goy, Andre ^{[4
]}

Casasnovas, Olivier ^{[5
]}

Smith, Stephen D. ^{[6
]}

Damaj, Gandhi ^{[7
]}

Doorduijn, Jeanette K. ^{[8
]}

Lamy, Thierry ^{[9
]}

Morschhauser, Franck ^{[10
]}

Panizo, Carlos ^{[11
]}

Shah, Bijal ^{[12
]}

Davies, Andrew ^{[13
]}

Eek, Richard ^{[14
]}

Dupuis, Jehan ^{[15
]}

Jacobsen, Eric ^{[16
]}

Kater, Arnon P. ^{[17
]}

Le Gouill, Steven ^{[18
]}

Oberic, Lucie ^{[19
]}

Robak, Tadeusz ^{[20
]}

Jain, Preetesh ^{[1
]}

Frigault, Melanie M. ^{[21
]}

Izumi, Raquel ^{[21
]}

Dorothy Nguyen ^{[21
]}

Patel, Priti ^{[21
]}

Yin, Ming ^{[21
]}

Dlugosz-Danecka, Monika ^{[22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Plymouth Univ, Sch Med, Plymouth, Devon, England

[3] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[4] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Hop Enfants, CHU Dijon, Dijon, France

[6] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[7] Inst Hematol Basse Normandie, Caen, France

[8] Erasmus MC, HOVON Lunenburg Lymphoma Phase Consortium 1 2, Rotterdam, Netherlands

[9] CHU Rennes, Rennes, France

[10] Univ Lille, CHU Lille, GRITA Grp Rech Formes Injectables & Technol Assoc, EA 7365, F-59000 Lille, France

[11] Clin Univ Navarra, Pamplona, Spain

[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[13] Univ Southampton, Canc Res UK Ctr, Fac Med, Southampton, Hants, England

[14] Border Med Oncol, Albury, Vic, Australia

[15] Hop Henri Mondor, AP HP, Unite Hemopathies Lymphoides, Creteil, France

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[17] Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam Univ Med Ctr, HOVON Lunenburg Lymphoma Phase Consortium 1 2, Amsterdam, Netherlands

[18] Hop Hotel Dieu, CHU Nantes, Nantes, France

[19] Inst Univ Canc Oncopole Toulouse, Toulouse, France

[20] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[21] Acerta Pharma, San Francisco, CA USA

[22] Jagiellonian Univ, Dept Haematol, Krakow, Poland

来源：

LEUKEMIA | 2019年 / 33卷 / 11期

关键词：

IBRUTINIB;

D O I：

10.1038/s41375-019-0575-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2762 / 2766

页数：5

共 50 条

[41] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
Witzig, T
Geyer, S
Ghobrial, I
Inwards, D
Fonseca, R
Kurtin, P
Ansell, S
Kaufmann, S
ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
[42] Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma.
Drach, J
Kaufmann, H
Woehrer, S
Chott, A
Zielinski, CC
Raderer, M
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 578S - 578S
[43] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Richardson, Paul
Jagannath, Sundar
Hussein, Mohamad
Berenson, James
Singhal, Seema
Irwin, David
Williams, Stephanie F.
Bensinger, William
Badros, Ashraf Z.
Vescio, Robert
Kenvin, Laurie
Yu, Zhinuan
Olesnyckyj, Marta
Zeldis, Jerome
Knight, Robert
Anderson, Kenneth C.
BLOOD, 2009, 114 (04) : 772 - 778
[44] SALVAGE TREATMENT WITH SINGLE-AGENT BENDAMUSTINE FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: AN ITALIAN MONOCENTRIC EXPERIENCE
Ricciuti, G.
Finolezzi, E.
Falorio, S.
Luciani, S.
Ranucci, E.
Angrilli, F.
HAEMATOLOGICA, 2014, 99 : 677 - 678
[45] Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
Prince, H. Miles
Adena, Michael
Smith, Dell Kingsford
Hertel, Judy
EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) : 93 - 99
[46] Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study
Wang, Michael
Rule, Simon
Zinzani, Pier Luigi
Goy, Andre
Casasnovas, Rene-Olivier
Smith, Stephen D.
Damaj, Gandhi
Doorduijn, Jeanette K.
Lamy, Thierry
Morschhauser, Franck
Panizo, Carlos
Shah, Bijal
Davies, Andrew
Eek, Richard
Dupuis, Jehan
Jacobsen, Eric
Kater, Arnon P.
Le Gouill, Steven
Oberic, Lucie
Robak, Tadeusz
Covey, Todd
Dua, Richa
Hamdy, Ahmed
Huang, Xin
Izumi, Raquel
Patel, Priti
Slatter, J. Greg
Jurczak, Wojciech
BLOOD, 2017, 130
[47] MANAGING ADVERSE EVENTS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB: CLINICAL EXPERIENCE FROM THE MD ANDERSON CENTER
Badillo, Maria
Nava, Diana
Dela Rosa, Maria
Rodriguez, Sara
Xu, Judy
Wang, Michael
ONCOLOGY NURSING FORUM, 2019, 46 (02)
[48] SINGLE-AGENT LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA FOLLOWING BORTEZOMIB: EFFICACY, SAFETY AND PHARMACOKINETICS FROM THE MULTICENTER PHASE II MCL-001 "EMERGE" TRIAL
Goy, A.
Sinha, R.
Vose, J.
Adler, H.
Bernstein, S.
Robertson, M.
Chen, N.
Zhang, L.
Cicero, S.
Fu, T.
Witzig, T.
HAEMATOLOGICA, 2013, 98 : 478 - 478
[49] Single-agent Aredia for relapsed/refractory multiple myeloma.
Berenson, JR
Webb, IJ
Anderson, K
Schlossman, R
Vescio, R
Doss, D
Goon, B
Swift, R
VonTeichert, J
Kowalski, M
Seaman, J
BLOOD, 1999, 94 (10) : 307B - 307B
[50] Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Tam, Constantine S.
Opat, Stephen
Simpson, David
Cull, Gavin
Munoz, Javier
Phillips, Tycel J.
Kim, Won Seog
Rule, Simon
Atwal, Siminder Kaur
Wei, Rachel
Novotny, William
Huang, Jane
Wang, Michael
Trotman, Judith
BLOOD ADVANCES, 2021, 5 (12) : 2577 - 2585

← 1 2 3 4 5 →